Press release summary
Allarity Therapeutics has added proteomics and cell-line research to its in-house medical laboratory, expanding a facility that already performs transcriptomics research and CLIA clinical testing.
The company said the added capabilities will support studies of stenoparib, its experimental dual PARP and WNT-pathway inhibitor, while allowing the laboratory to take on projects for external partners. Its nCounter Pro instrument, already used for transcriptomics and clinical services, can now support proteomics research with the nCounter Human Tumor Signaling Protein Panel. The panel measures about 300 protein targets.
Allarity said bringing more work in-house will not change its current cash runway and could reduce research costs. Those financial and operational benefits are company expectations rather than independently demonstrated outcomes.
Why it matters for laboratories
The expansion illustrates how a clinical-stage drug developer can combine transcriptomic, targeted-proteomic, cell-based, and clinical testing capabilities under one laboratory program. That structure can shorten feedback between mechanism studies and biomarker development. Laboratories evaluating similar consolidation should account for method validation, staff competency, quality-system boundaries, and the different oversight required for research and clinical testing.
Original source: Allarity Therapeutics press release, Sept. 28, 2026.
Leave a Reply